1. Meigs JV: Tumors of the female pelvic organs. New York: Mac-millan, 1934.
2. Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42: 101-104, 1975.
3. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA: The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 47:159-166, 1992.
4. Hoskins WJ, McGuire WP, Brady MF, et al: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170:974-979, 1994.
5. Norton L: Theoretical concepts and the emerging role of taxanes in adjuvant therapy. The Oncologist 6(Suppl 3):30-35, 2001.
6. Goldie JH, Coldman JA: A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727-1733, 1979.
7. Chi DS, Liao JB, Leon LF, et al: Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 82:532-537, 2001.
8. Bristow RE, Tomacruz RS, Armstrong DK, et al: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248-1259, 2002.
9. Berek JS, Hacker NF, Lagasse LD, et al: Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol 61:189-193, 1983.
10. Bristow RE, Lagasse LD, Karlan BY: Secondary surgical cytore-duction for advanced epithelial ovarian cancer: patient selection and review of the literature. Cancer 78:2049-2062, 1996.
11. Berek JS, Bertelsen K, du Bois A, et al: Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999; 10(Suppl 1):S87-S92.
12. Segna R, Dottino PR, Mandeli JPP, et al: Secondary cytoreduc-tion for ovarian cancer following cisplatin therapy. J Clin Oncol 11:434^39, 1993.
13. Lichtenegger W, Sehouli J, Buchmann E, et al: Operative results after primary and secondary debulking operations in advanced ovarian cancer (AOC). J Obstet Gynaecol Res 24(6):447-451, 1998.
14. Eisenkop SM, Friedman RL, Spirtos NM: The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88:144-153, 2000.
15. Zang RY, Zhang ZY, Li ZT, et al: Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol 75:24-30, 2000.
16. Scarabelli C, Gallo A, Carbone A: Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 83:504-512, 2001.
17. Zang Ry, Li ZT, Zhang ZY, et al: Surgery and salvage chemotherapy for Chinese women with recurrent advanced epithelial ovarian carcinoma: a retrospective case-control study. Int J Gynecol Cancer 13:419-427, 2003.
18. Zang Ry, Li ZT, Tang J, et al: Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 100:1152-1161, 2004.
19. Ayhan A, Gultekin M, Taskiran C, et al: The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience. Am J Obstet Gynecol 194:49-56, 2006.
20. Chi DS, McCaughty K, Diaz JP, et al: Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106:1933-1939, 2006.
21. Harter P, du Bois A, Hahmann M, et al: Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13:1702-1710, 2006.
22. Salani R, Santillan A, Zahurak ML, et al: Secondary cytoreduc-tive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 109:685-691, 2007.
23. Tebes SJ, Sayer RA, Palmer JM, et al: Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 106:482-487, 2007.
24. Morris M, Gershenson DM, Wharton JT: Secondary cytoreduc-tive surgery in epithelial ovarian cancer: nonresponders to firstline therapy. Gynecol Oncol 33(1):1-5, 1989.
25. Tay EH, Grant PT, Gebski V, Hacker NF: Secondary cytoreduc-tive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol 99:1008-1013, 2002.
26. Leitao MM, Kardos S, Barakat RR, Chi DS: Tertiary cytoreduc-tion in patients with recurrent ovarian cancer. Gynecol Oncol 95:181-185, 2004.
27. Onda T, Yoshikawa H, Yasugi T, et al: Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patient selection. Br J Cancer 92:1026-1032, 2005.
28. Munkarah A, Levenback C, Wolf JK, et al: Secondary cytoreduc-tive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol 81:237-241, 2001.
29. Cormio G, di Vagno G, Cazzolla A, et al: Surgical treatment of recurrent ovarian cancer: report of 21 cases and a review of the literature. Eur J Obstet Gynecol Reprod Biology 86:185-188, 1999.
30. Vaccarello L, Rubin SC, Vlamis V, et al: Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol Oncol 57:61-65, 1995.
31. Janicke F, Holscher M, Kuhn W, et al: Radical surgery procedure improves survival time in patients with recurrent ovarian cancer. Cancer 70:2129-2136, 1992.
32. Gronlund B, Lundvall L, Christensen IJ, et al: Surgical cytore-duction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. Eur J Surg Oncol 31:67-73, 2005.
33. Gadducci A, Iacconi P, Cosio S, et al: Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol 79:344-349, 2000.
34. Gungor M, Ortac F, Arvas M, et al: The role of secondary cyto-reductive surgery for recurrent ovarian cancer. Gynecol Oncol 97:74-79, 2005.
35. Harter P, du Bois A: The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence. Curr Opin Oncol 17:505-514, 2005.
36. Uzan C, Morice P, Rey A, et al: Outcomes after combined therapy including surgical resection in patients with epithelial ovarian cancer recurrence (s) exclusively in lymph nodes. Ann Surg Oncol 11:658-664, 2004.
37. Funt SA, Hricak H, Abu-Rustum N, et al: Role of CT in the management of recurrent ovarian cancer. AJR Am J Roentgenol 182:393-398, 2004.
38. Sugarbaker PH: Management of peritoneal surface malignancy: appendix cancer and pseudomyxoma peritonei, colon cancer, gastric cancer, abdominopelvic sarcoma, and primary peritoneal malignancy. In Bland KI, Daly JM, Karakousis CP (eds): Surgical Oncology: Contemporary Principles and Practice. New York: McGraw-Hill, 2001, pp 1149-1176.
39. Yoon SS, Jarnagin WR, DeMatteo RP, et al: Resection of recurrent ovarian or fallopian tube carcinoma involving the liver. Gynecol Oncol 91(2):383-388, 2003.
40. Chung HH, Kang WJ, Kim JW, et al: Role of [18F]FDG PET/ CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging 34(4):480-486, 2007.
41. Torizuka T, Nobezawa S, Kanno T, et al: Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose. Eur J Nucl Med Mol Imaging 29(6):797-803, 2002.
42. Lenhard SM, Burges A, Johnson TR, et al: Predictive value of PET-CT imaging versus AGO-scoring in patients planned for cytoreductive surgery in recurrent ovarian cancer. Eur J Obstet Gynecol Reprod Biol 140:263-268, 2008.
43. Bristow RE, del Carmen MG, Pannu HK, et al: Clinically occult recurrent ovarian cancer: patient selection for secondary cytore-ductive surgery using combined PET/CT. Gynecol Oncol 90(3):519-528, 2003.
44. Bristow RE, Puri I, Chi DS: Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 112:265-274. Epub 2008 Oct 19.
45. Helm CW, Randall-Whitis L, Martin III RS, et al: Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol 105:90-96, 2007.
46. Cotte E, Glehen O, Mohamed F, et al: Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg 31(9):1813-1820, 2007.
47. Meyn RE, Corry PM, Fletcher SE, et al: Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminechloroplatinum(II). Cancer Res 40:1136-1139, 1980.
48. Alberts DS, Peng YM, Chen HS, et al: Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. J Natl Cancer Inst 65:455-461, 1980.
Borderline Epithelial Ovarian Tumors, Sex Cord-Stromal Tumors, and Germ Cell Tumors
Was this article helpful?
Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.